Mission Statement

Recognising the rapid progress and growing importance of therapeutic application of nuclear medicine, the NMEU Therapy working group was created to give voice to this evolving, cutting-edge sector. The working group brings insights from the therapeutic side of nuclear medicine into the activities of NMEU, alongside the role of diagnostics.

The Therapy working group meets with the other working groups to cross discuss issues of shared relevance, related to, but not limited to, radiation protection, dosimetry, medicinal products, procurement, regulation, radiation protection, reimbursement policies. The Working group develops opinions and positions on therapeutic perspective and works to ensure that these positions are well recognised and featured in key policy files at both EU and national level. Among its other activities, the group identifies and interacts with relevant stakeholders and EU institutions, collaborates and participates in official publications, public responses and further NMEU engagement activities.

The scope of the working group’s activities is two-fold. Firstly, the group strives to establish the therapeutic applications of nuclear medicine as innovative treatment paradigm – not only in the field of oncology but also in other disease areas. Secondly, the group intends to reduce the gap between industry and academic research and encourage greater collaboration between the two parts to be “stronger together for patients” (e.g.: through organisation of seminars, hot topics sessions, development of short papers for dissemination, etc.)

Ultimately, the group seeks to promote the adoption of therapeutic applications of nuclear medicine through suitable legislation and equipped healthcare systems. In this way, we will achieve a better regulatory and policy environment for the uptake of therapeutic nuclear medicine at European and national levels.

The Group

Chair : Jean Bonnet
Head of Strategy, Sales & Marketing – IRE

Vice-Chair : Jean-François Gestin

Supervisor : Lutz Helmke
Vorstand Segment Radiopharma – Eckert & Ziegler

Dirk Bernhardt
VP Global Market Access – ITM Radiopharma

Samy Bertrand
Product Manager – IBA Group

Evelyne Boos
Medical Scientific Director – Curium Group

Jean-Michel Geets
Integralab Business Developer – IBA Group

Alex Gibbs
Head of Global Oncology Policy – Bayer

Dimitry Ginzburg
R&D Manager – Rotem Industries

Ira Goldman 
Vice President, Global Public Policy and Government Relations – Lantheus

Avşar Kumral
Medical Manager – Monrol

Sophie Letournel
Governance and Communication Director – Oranomed

Mario Malinconico
Product Manager & Senior Radiochemist – Comecer

Steven Max
Senior Director – Compound Development Team Leader – Janssen Cilag International

Matteo Melandri
Key Account and Area Manager – Tema Sinergie

Raphael Ortiz
Chief Operating Officer – Telix Pharmaceuticals

Jasminka Taleska
Global Director RLT Policy strategy – AAA Novartis

Guy Turquet de Beauregard
Honorary President – NMEU

Corentin Warnier
Head of Chemistry – Trasis

Adrien Reymond
Business Development and Regulatory Affairs Director – Atonco

Lorenzo Pompignoli
Tema SinergieSales Engineer

Akiharu Otaka
General Manager, BD & IP Department, R&D Division -Nihon Medi Physics 

Shopping Basket